Evidence map›Paper›PMID 37601849›Full record

ArticleEJHaem2023

Leukaemic cells expressing ETV6::FRK are sensitive to dasatinib in vivo.

Azusa Mayumi, Toshihiko Imamura, Hideki Yoshida, Shinya Osone, Takahiko Yasuda, Tomoko Iehara

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Azusa MayumiDepartment of Paediatrics Kyoto Prefectural University of Medicine Kyoto Japan.ORCID https://orcid.org/0000-0002-2091-2619
Toshihiko ImamuraDepartment of Paediatrics Kyoto Prefectural University of Medicine Kyoto Japan.
Hideki YoshidaDepartment of Paediatrics Kyoto Prefectural University of Medicine Kyoto Japan.
Shinya OsoneDepartment of Paediatrics Kyoto Prefectural University of Medicine Kyoto Japan.
Takahiko YasudaClinical Research Center Nagoya Medical Centre National Hospital Organization Nagoya Japan.
Tomoko IeharaDepartment of Paediatrics Kyoto Prefectural University of Medicine Kyoto Japan.
Kyoto Prefectural University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ETV6::Fyn-related kinase (FRK), which is a Src family tyrosine-kinase-related fusion gene and firstly identified in our patient with paediatric high risk B cell precursor acute lymphoblastic leukaemia (B-ALL), has no evidence of efficacy of tyrosine kinase inhibitor in vivo. We performed functional analysis of ETV6::FRK to establish molecular targeting therapy and determined that dasatinib could abrogate proliferation activity of ETV6::FRK through the repression of FRK-STAT3/STAT5 pathway in vitro and significantly extended the survival time of the xenografted mice in vivo (

Indexed as

acute lymphoblastic leukaemiaB‐ALLdasatinibETV6::FRK

Identifiers

PMID37601849
PMCPMC10435712
OpenAlexW4367853319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.